The Star Beacon; Ashtabula, Ohio

World, nation, state

February 23, 2013

FDA approves new breast cancer drug

WASHINGTON — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

“This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it’s very kind and gentle on the patients — there’s no hair loss, no nausea, no vomiting,” said Dr. Melody Cobleigh of Rush University Medical Center. “It’s a revolutionary way of treating cancer.”

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche’s Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug’s sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

 

1
Text Only
World, nation, state
  • Poll finds Clinton trouncing entire GOP field

    Hillary Clinton isn’t only the strong front-runner for the 2016 Democratic presidential nomination, but she’s well ahead of every potential Republican rival, according to a new McClatchy-Marist Poll.
     

    April 16, 2014

  • Ukraine bares teeth against eastern uprising

    In the first Ukrainian military action against a pro-Russian uprising in the east, government forces repelled an attack Tuesday by about 30 gunmen at an airport, beginning what the president called an “anti-terrorist operation” to try to restore authority over the restive region.
     

    April 16, 2014

  • U.N. Security Council sees grim images of Syrian dead

    The U.N. Security Council fell silent Tuesday after ambassadors viewed a series of ghastly photographs of dead Syrian civil war victims, France’s ambassador said. The pictures showed people who were emaciated, with their bones protruding, and some bearing the marks of strangulation and repeated beatings, and eyes having been gouged out.

    April 16, 2014

  • U.S.: Russia causing Ukraine unrest

    The White House on Monday said there was “overwhelming evidence” that Russia is fomenting unrest in eastern Ukraine, but suggested that President Barack Obama has not yet concluded that Vladimir Putin’s actions warrant broader sanctions on key Russian economic sectors.

    April 15, 2014

  • Woman arrested after dead babies found

    A Utah woman accused of killing seven babies she gave birth to over 10 years was arrested Sunday after police discovered the tiny bodies stuffed in separate cardboard boxes in the garage of her former home.

    April 14, 2014

  • Rome man killed in crash

    The Ohio State Highway Patrol Chardon Post is investigating a fatal crash that took place just after midnight Sunday.

    April 14, 2014

  • 3 dead in shootings at Kansas facilities

    Three people died Sunday when a gunman opened fire outside the Jewish Community Center and a senior living facility in Johnson County, Kan.

    April 14, 2014

  • High fees eroding many 401(k) accounts

    It’s the silent enemy in our retirement accounts: High fees.
    And now a new study finds that the typical 401(k) fees — adding up to a modest-sounding 1 percent a year — would erase $70,000 from an average worker’s account over a four-decade career compared with lower-cost options. To compensate for the higher fees, someone would have to work an extra three years before retiring.

    April 14, 2014

  • Abortion in cases of rape: New rifts in old debate

    Poll after poll over many years has shown that Americans overwhelmingly support legal access to abortion for women impregnated by rape. Yet the issue remains divisive, as demonstrated by two current rifts — one involving U.S. aid policy overseas, the other highlighting strategy differences within the U.S. anti-abortion movement.

    April 13, 2014

  • Ohio geologists link small quakes to fracking

    Geologists in Ohio have for the first time linked earthquakes in a geologic formation deep under the Appalachians to hydraulic fracturing, leading the state to issue new permit conditions Friday in certain areas that are among the nation’s strictest.

    April 12, 2014

House Ads
Parade
Magazine

Click HERE to read all your Parade favorites including Hollywood Wire, Celebrity interviews and photo galleries, Food recipes and cooking tips, Games and lots more.
AP Video